These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 15954135)
1. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135 [TBL] [Abstract][Full Text] [Related]
2. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Stathis P; Konitsiotis S; Tagaris G; Peterson D; Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Lyons KE; Pahwa R Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814 [TBL] [Abstract][Full Text] [Related]
4. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461 [TBL] [Abstract][Full Text] [Related]
5. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease. Tousi B; Subramanian T Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966 [No Abstract] [Full Text] [Related]
6. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218 [TBL] [Abstract][Full Text] [Related]
7. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088 [TBL] [Abstract][Full Text] [Related]
8. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
9. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias. Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945 [No Abstract] [Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. Wong KK; Alty JE; Goy AG; Raghav S; Reutens DC; Kempster PA Mov Disord; 2011 Jul; 26(8):1552-5. PubMed ID: 21538524 [TBL] [Abstract][Full Text] [Related]
11. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease]. Cersósimo MG; Scorticati MC; Micheli FE Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808 [TBL] [Abstract][Full Text] [Related]
12. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM; Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530 [TBL] [Abstract][Full Text] [Related]
13. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867 [TBL] [Abstract][Full Text] [Related]
15. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Rascol O; Bronzova J; Hauser RA; Lang AE; Sampaio C; Theeuwes A; van de Witte SV Parkinsonism Relat Disord; 2012 May; 18(4):370-6. PubMed ID: 22316635 [TBL] [Abstract][Full Text] [Related]
16. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606 [TBL] [Abstract][Full Text] [Related]
17. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820 [TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease home diary: further validation and implications for clinical trials. Hauser RA; Deckers F; Lehert P Mov Disord; 2004 Dec; 19(12):1409-13. PubMed ID: 15390057 [TBL] [Abstract][Full Text] [Related]
19. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease. Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540 [TBL] [Abstract][Full Text] [Related]
20. Levetiracetam in tardive dyskinesia: an open label study. Konitsiotis S; Pappa S; Mantas C; Mavreas V Mov Disord; 2006 Aug; 21(8):1219-21. PubMed ID: 16637037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]